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Many estrogen-receptor- (ER-) expressing breast cancers become refractory to ER-based therapies. New antitumor drugs like
aminoflavone (AF) and benzothiazoles (Bzs) have been developed and have exquisite antitumor activity in ER+MCF-7 and T47D
cells and in a MCF-7 nude mouse model. ER(−) breast cancer cells like MDA-MB-231 are less susceptible. We previously found
in MCF-7 cells that these drugs activate the aryl hydrocarbon receptor (AhR) via translocation to the nucleus, induction of AhR-
specific DNA binding activity, and expression of CYP1A1, whose transcription is controlled by the AhR-ARNT transcription
factor. CYP1A1 metabolizes AF and Bz to a species which directly or after further metabolism damages DNA. In contrast an AhR-
deficient variant of MCF-7 or cells with predominantly nuclear AhR expression, such as MDA-MB 231, are resistant. Thus, these
drugs, unlike other neoplastic agents, require AhR-mediated signaling to cause DNA damage. This is a new treatment strategy for
breast cancers with intact AhR signaling.
1. Treatment Advances in Breast Cancer
Metastatic breast cancer is currently incurable, and novel
strategies that might become useful treatments are needed.
In the past decade, Herceptin directed against the HER2/neu
oncoprotein and aromatase antagonists have entered clinical
practice [1, 2]. Despite these advances, cytotoxicity evoked
by drugs directed at DNA remains an interesting option [3].
However, these cytotoxics are nonspecific. Ideally, new breast
cancer cytotoxics would engage some aspect of breast cancer
biology to convey selective toxicity to breast cancer cells.
2. Aryl Hydrocarbon Receptor
The aryl hydrocarbon receptor (AhR) was initially defined
as a receptor for environmental toxins such as dioxin. It
belongs to the helix-loop-helix transcription factor family.
Other members of this family are AhR nuclear translocator
(ARNT); Drosophila proteins, SIM and PER, and hypoxia-
inducible factor 1α (HIF 1α) [4–7]. AhR is a ligand-activated
transcription factor. The most commonly known ligands
of AhR are polycyclic and polyhalogenated hydrocarbons
(benzopyrene, 3-methyl-colantrene), xenobiotics (pheno-
barbital), and other pesticides like tetrachlorodibenzo-p-
dioxin (TCDD).
AhR is localized within the cell cytosol constitutively
where it is part of an inactivated complex composed of two
heat-shock proteins: heat-shock protein 90 (Hsp90) and a
43 kDa protein known as AIP (Figure 1). The role of Hsp90
involves a chaperone activity that keeps AhR in a favorable li-
gand-binding configuration while it prevents its nuclear
translocation. Hydrophobic ligands of AhR enter the cell
by simple diﬀusion and bind to the receptor associated to
Hsp90. Ligand binding to the receptor triggers a conforma-
tional change in AhR to a form that exhibits stronger aﬃnity
for DNA. This event leads to dissociation of the cytoplasmic
2 International Journal of Breast Cancer
Cytosol
XRE
Transcription
AhR
ARNT
Dimerisation
DNA
binding
ARNT
AhR
AhR
Ligand
Ligand
Ligand
Ligand
Ligand
Hsp90Hsp90
Hsp90Hsp90
AhR
binding
Ligand Nucleus
Figure 1: The aryl hydrocarbon signaling pathway.
complex and to AhR nuclear translocation.Within the nucle-
us, AhR interacts with ARNT forming a heterodimer that
binds to specific DNA sequences called xenobiotic response
elements (XREs). This binding leads to the transcriptional
activation of genes that possess these XREs in their promoter
sequences. Some of the genes activated by AhR encode
phase I and II metabolic enzymes such as cytochrome P450
(CYP) 1A1, CYP1A2, and CYP1B1. AhR activation was first
described as a cellular response to promote elimination of
ambient contaminants and xenobiotics [8–10]. In humans,
AhR is localized in liver, lungs, kidneys, placenta, lympho-
cytes, ovary, and breast. AhR/ARNT complex activation is
tissue-specific and depends on co-regulators present in dif-
ferent cell types [9].
3. Estrogen Receptor-Aryl Hydrocarbon
Receptor Crosstalk
It was demonstrated that in breast cancer cells, AhR ligands
have the capacity to bind to ER and potentially interfere with
ER signaling [11]. Also, it has long been known that estrogen
can be metabolized by AhR-driven genes such as CYP1B1 to
yield toxic metabolites that in some cases have been proposed
to act as genotoxins [12]. This has led to the hypothesis
that mutual modulation of AhR and ER signaling functions
may be possible. Indeed, previous publications have shown
that certain AhR ligands can have antiproliferative eﬀects
alone or in conjunction with ER antagonist administration
with evidence of antitumor activity in breast cancer models
[13]. How estrogen and its antagonist will agonize, have no
eﬀect, or amplify AhR-related signaling functions is a key
unresolved question.
4. Benzothiazoles and Aminoflavone:
AhR-Targeted Therapies for Breast Cancer
Empirical screening in the NCI cell line anticancer drug
screen has revealed two types of molecules, the benzothia-
zoles (Bzs) [14–18] and aminoflavone (AF) [19], which
are noteworthy for diﬀerential cytotoxicity. “Sensitive” cell
lines have total growth inhibition (TGI) between 0.1 and
1 μM, while “resistant” cell lines are refractory to Bz and AF
concentrations <10 μM. Among the consistently sensitive cell
lines to both compound classes were the ER(+) breast cancer
cell lines MCF-7 and T47D [18, 19]. While certain other cell
types in this screen did show susceptibility, for example, renal
cancer, in the breast cancer panel, optimal cytotoxicity of
these drugs was seen in cell lines expressing estrogen receptor
(ER(+)) [18]. Detailed mechanistic studies for both Bzs
and AF have revealed that “sensitive” cells can activate AhR
signaling, as might be expected from their planar nature [20].
This causes expression of CYP1A1 and in certain cell lines
CYP1B1. Prior work had shown that CYP1A1 canmetabolize
Bzs and AF to produce DNA-damaging metabolites [14–19].
5. Benzothiazoles’ Mechanism of Action
Previous results from our research group have demonstrated
that the antitumor eﬀect of compounds of the 2-(4-amino-
3-methylphenyl) benzothiazole group (DF 203, NSC 674495;
5F 203, NSC 703786) (Figure 2) is mediated by AhR in
MCF-7 breast tumor cells [15, 17, 21]. Currently Phortress,
the lysine amide prodrug of 2-(4-amino-3-methylphenyl)-
5-fluorobenzothiazole (5F 203), is under Phase I clinical
evaluation sponsored by the Cancer Research UK [21–29].
DF 203 preceded 5F 203 in the development of Phortress.
A fluorine atom was introduced to thwart deactivating
metabolism of DF 203 by CYP1A1 to inactive hydroxy-
lated biotransformation products [23]. We observed that
treatment of MCF-7 with Bzs resulted in activation of
AhR. Figure 3 shows AhR translocation to the nucleus after
treatment with DF 203 in sensitive cells like MCF-7 but not
in resistant cells like MDA-MB-435. However, a controversy
exists concerning the origin ofMDA-MB-435 cells. In the last
years it has been shown that these cells are derived from a
melanoma [15].
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Figure 2: Chemical structures of antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
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Figure 3: DF 203 causes an increase in immunoreactive nuclear AhR in MCF-7 cells. MCF-7 and MDA-MB-435 were treated with 0.1%
DMSO, 1 μM DF 203, or 20 μM β-naphthoflavone for 1 h. Determination of immunoreactive AhR in cytoplasmic and nuclear fractions was
performed by western blot. β-NF: β-naphthoflavone [15].
In a similar way when we used 5F 203 we observed an
increase in AhR transcriptional activity (increase in XRE-lu-
ciferase activity (Figure 4(a)) and formation of protein/DNA
complexes bound to XRE Figure 4(b)) [17].
We also observed an increase in the transcription of
AhR target genes such as CYP1A1/1B1, but AHR 100 cells,
derived fromMCF-7 which do not express the AhR receptor,
were resistant to 5F 203, and the treatment did not induce
activation of CYP1A1 (Figure 5) [17].
We also demonstrated that in MCF-7 cells, treatment
with 5F 203 prevents entry into G2/M and S phase and
causes apoptosis, which was not observed in AHR 100 cells
(Figure 6) [17]. These data suggested that activation of AhR
was necessary for the antitumor activity of the benzothiazoles
in MCF-7.
The mechanism of action of benzothiazoles is represent-
ed in Figure 7.
6. Aminoflavone, an Alternative Therapy for
ER+ Breast Cancer Cell Lines Resistant to
Antihormone Treatment
AF (NSC 686288) is a novel anticancer agent (Figure 8). Pre-
vious work from our research group demonstrated that AF
is a ligand of AhR [19]. It was proposed that induction of
CYP1A1 and high covalent binding of AF metabolites are
markers to predict sensitivity to this drug in breast and renal
tumors [19, 20]. AF derivative compound, aminoflavone
prodrug (AFP464, NSC710464), has currently entered phase
II clinical trials (Figure 8).
AF activity has been linked to the presence of cytoplasmic
AhR and nuclear translocation of the AhR-AF complex fol-
lowed by induction of cytochrome P450 (CYP) 1A1, activa-
tion of sulfotransferase 1A1 (SULT1A1), and DNA damage
caused by metabolites. The latter is exemplified by the occur-
rence of gamma-histone 2AX (H2AX) phosphorylation con-
sistent with induction of DNA single-strand breaks and
DNA-protein cross-links (Figure 9) [30].
AF has shown exquisite in vitro sensitivity toward es-
trogen-receptor-positive (ER+) breast cancer cell lines and in
vivo activity in MCF-7 xenografts (Figure 10) [19].
In contrast, ER− breast cancer cell lines, like MDA-MB-
431, were resistant to AF. Crosstalk between AhR and ER
signaling pathways has been established. It was shown that
ligand-bound AhR can mimic estrogens and redirect ER
from ER target genes to AhR target genes, such as CYP1A1
[13]. Given these facts, patients that might benefit most
from AF treatment in the clinic could be those with ER+,
endocrine-therapy-resistant breast cancers.
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Figure 4: (a) 5F 203 induces binding to the XRE sequence of CYP1A1. MCF-7 and AHR100 cells were transfected with XRE-luciferase
(pTX.Dir.) or pT81. A schematic of the respective construct is shown below the panel. Transfected cells were treated with DMSO, TCDD
(10 nM), or 5F 203 (1 μM) for 9 h. XRE-luciferase activity was determined normalizing to the amount of Renilla reniformis luciferase. The
values are expressed as luciferase levels relative to control. (b) 5F 203 induces protein/DNA complexes on the XRE sequence of the CYP1A1
promoter. Nuclear extracts (20mg) prepared from MCF-7 cells treated with 0.1% DMSO control (lane 1), TCDD (10 nM, 1 h) (lane 2), or
5F 203 (1 μM, 1 h) (lane 3) were incubated with labeled XRE sequence derived from the CYP1A1 promoter for 10min at room temperature.
Free DNA and bound DNA were separated as described. In competition experiments, nuclear extracts from MCF-7 cells treated with 5F
203 (1 μM, 1 h) were incubated with 4 μg of anti-AhR antibody (lane 6), 100-fold excess of unlabeled XRE oligonucleotide (lane 7), 100-fold
excess of unlabeled Sp1 oligonucleotide (lane 8), or 4 μg of IgG antiserum (lane 9). Protein/DNA complexes from AHR100 cells were resolved
in the same gel. Nuclear extracts from these cells (20mg) treated with DMSO (lane 4) or 5F 203 (1 μM, 1 h) (lane 5) were incubated with
radioactive XRE and resolved by the same procedure [17].
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Figure 5: (a) 5F 203 induces CYP1A1 activity in MCF-7 but not
in AHR100 cells. MCF-7 and AHR100 cells were incubated for 24 h
with DMSO (0.1%) and 5F 203 (1 μM) for 24 h and assayed for
CYP1A1 enzyme activity by EROD assay, n = 4 ± s.d. (b) 5F 203
induces CYP1A1 and CYP1B1 mRNA levels in sensitive (MCF-7)
cells. MCF-7 and AHR100 cells were treated with 5F 203 (1 μM)
for 24 h, RNA was isolated from control and treated samples, and
CYP1A1 and CYP1B1 gene expression were measured by real-time
RT-PCR as described. Data are shown as fold induction of treated
cells relative to constitutive expression in control cells ± s.d., n = 7
(samples from two independent experiments) [17].
Recent work was performed to test whether breast can-
cers resistant to antihormone treatments retain sensitivity to
AF. The AF response in a panel of molecularly well defined
breast cancer cell lines was evaluated. The latter included
MCF-7 (ER+) and its resistant subclones MCF-7/Her2-18
(ER+), MCF-7TAM1 (ER+), LTLC (ER+high), and LTLT
(ERvery low); T47D (ER+), MDA-MB-231 (ER−); Hs5718ti8
(ER−); MCF10A (ER−). Antiproliferative eﬀects were mea-
sured by MTT assay, and concentrations that inhibit cell
growth by 50% (IC50) of the control were established for each
cell line. The response to AF was compared to ER and AhR
expression by western blot and immunocytochemistry. AF
potently inhibited the growth of all ER+ breast cancer cell
lines at nanomolar concentrations irrespective of hormone
resistance (mean IC50s: MCF-7 = 16 nM; MCF-7/Her2-18 =
20 nM; MCF-7TAM1 = 25 nM; T47D = 14 nM; LTLC =
100 nM), whereas the ER− breast cancer cell lines (mean
IC50s: MDA-MB-231 = 25 μM; Hs5718ti8 = 18 μM; LTLT
>50 μM) and the ER− breast epithelial line MCF10A (IC50 =
3μM) were 2- to 3-log-fold less sensitive. Interestingly, AhR
was predominantly localized in the nuclei of all ER− cell
lines, but was expressed in the cytoplasm of ER+ cells. MCF-
7/Her2-18 and MCF-7TAM1, which are both tamoxifen-re-
sistant subclones of MCF-7 (IC50s 4–OH–tamoxifen 3 and
10 μM) and LTLC, a letrozole-resistant clone (IC50 > 1μM),
retained a sensitivity to AF that was similar to parental MCF-
7 cells [31, 32].
In order to examine the role of ER in AF sensitivity, AF
was combined with a fixed concentration (100 nM) of the
“pure” antiestrogen Faslodex in MCF-7 cells. The IC50 for
AF plus Faslodex was found to be 0.5 nM, suggesting a syner-
gism between the two drugs. To further prove that ER-AhR
crosstalk is correlated with AF sensitivity, MDA-MB-231 cells
(ER−) were stably transfected with human estrogen recep-
tor-α, rendering them ER+. It was found that the ER+MDA-
MB-231 cells had cytoplasmic AhR and were 5 times more
sensitive to AF (IC50 = 5μM) compared to parental- and
vector-transfected cells.
The authors concluded that the cytoplasmic AF-AhR
complex can activate unliganded ER to enhance AhR target
gene expression [31, 32].
7. Vorinostat Can Sensitize Triple
Negative Breast Cancer Cell Lines to
Aminoflavone Prodrug
AFP464 exhibits diﬀerential in vitro cytotoxicity in breast
cancer cell lines with inhibitory 50% (IC50) concentrations
ranging from 0.01 to 30 μM. AFP464 plasma levels that can
safely be reached in patients are ∼1 μM. In sensitive cells,
AFP464 induces AhR-mediated cytochrome P450- (CYP-)
dependent xenobiotic response and cell death. In resistant
cells, the CYP system was not induced. Recent experiments
showed that a panel of 10 luminal and basal A type breast
cancer cells irrespective of resistance to antihormone thera-
pies (e.g., tamoxifen refractory MCF7TAM1 cells) were ex-
quisitely sensitive to AFP464 with IC50s between 0.01 and
0.025 μM, whereas “triple-negative” breast cancer (TNBC)
cell lines with a basal B-like gene cluster were resistant
[33, 34]. Drug concentrations needed to inhibit the growth of
basal B-like cells by 50% (25–30 μM) may not be achieved in
patients. Thus, it was proposed that in TNBCs, combination
treatments will be needed and that agents modifying gene
transcription, such as the histone deacetylase inhibitor,
vorinostat, might be suitable combination partners. To test
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this hypothesis, combination experiments were employed
using the fixed IC50 ratio method and treated MDA-MB-231
and Hs578T cells were treated for 24, 48, and 72 hrs with
vorinostat followed by AFP464 for a total of 5 days. It was
found that AFP464 and vorinostat can act synergistically; in
Hs578T cells, combination indices (CIs) of <0.3 were seen
after pretreatment with vorinostat for 24 hrs, reducing the
AFP464 IC50 from 20 μM to 0.5 μM; in MDA-MB-231 cells,
CIs indicating synergism (<1) were observed when adding
AFP464 after 48 and 72 hrs pretreatment with vorinostat.
This led to a 25-fold sensitization to AFP464 (IC50 = 1μM)
[33, 34].
To study mechanisms that could explain the sensitization
of TNBC cell lines to AFP464, real-time PCR to assess the
induction of CYP1A1 and CYP1B1 after vorinostat treat-
ment, western blotting to determine estrogen receptor reac-
tivation, and transcriptional profiling using Illumina Human
HT-12 v3 whole-genome expression BeadChips were per-
formed. In MDA-MB-231 cells vorinostat treatment restored
the AhR-dependent xenobiotic response to AFP464 by in-
ducing both CYP1A1 and B1; also estrogen receptor expres-
sion was detectable in MDA-MB-231 and Hs578T cells at
the protein level, consistent with driving these TNBCs into
a more luminal-like genotype. These data indicated the use-
fulness of gene expression profiling in selecting patients for
AFP464 treatment. While single agent therapy might present
an option for hormone refractory luminal and basal A type
patient populations, breast cancer patients with basal B-like
tumors will require combination therapies, for example, with
vorinostat. Pretreatment of TNBCs with vorinostat could
sensitize these tumors to AFP464 [34].
8. Nuclear Expression of the Aryl
Hydrocarbon Receptor Elicits Resistance to
Aminoflavone Prodrug
Other studies were performed to test whether primary hu-
man tumors would also show nuclear or cytoplasmic AhR
and to assess the extent to which AhR was expressed. 165 ar-
chival human tissues were analyzed comprising breast, pan-
creas, ovarian, and renal cell cancers. It was found that the
59 percent of all cases had detectable AhR, amongst those 78
percent exhibited cytoplasmic AhR and 22 percent nuclear
AhR. Pancreatic (70%) and breast cancers (46%) showed the
highest percentage of cytoplasmic AhR [34].
Together these data indicate that AhR has a distinct dis-
tribution pattern in tumor cells. Cytoplasmic AhR expression
elicits sensitivity to the AhR ligand AFP464. If AhR is located
in the nucleus, the xenobiotic response is impaired and
AFP464 cannot be activated [35].
9. Conclusions
These results lead one to the conclusion that AF and Bzs, two
structurally dissimilar compounds, share certain character-
istics in their mechanism of action but are certainly not iden-
tical in their pattern of activity. Both compounds activate
the AhR signaling pathway leading to an increase in CYP1A1
and CYP1B1 gene expression in drug-sensitive MCF-7 cells
but not in resistant cells like MDA-MB-435, PC-3, or
MCF-7 AhR-deficient AHR100 cells. Although activation of
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Figure 10: Cytotoxicity of aminoflavone in vitro and in vivo.
(a) Selective cytotoxicity of aminoflavone to MCF-7 breast tumor
cells. Cell lines were seeded into 24-well plates and allowed to
grow for 48 hours. Cells were treated with 10−10 to 10−5 mol/L
aminoflavone for an additional 72 hours. Cell monolayers were
stained with sulforhodamine (b) and protein was determined
spectrophotometrically. Points, mean ± SD (n = 10). SD was
<5% for all drug concentrations and was omitted for purpose of
graphical clarity. (b) Antitumor activity of aminoflavone against
MCF-7 breast tumor xenografts. Treatments were given on a QD ×
5 schedule beginning on day 13. There were 20 mice in the vehicle
control group and 6 mice per dose of aminoflavone in the treated
groups [19].
the AhR signaling pathway by the drugs may be necessary
for increases in CYP1A1 and CYP1B1 gene expression, addi-
tional metabolic conversions may be necessary to produce
cytotoxicity. These results suggest that the cytotoxicity of AF
and Bz in a sensitive breast tumor cell line is the result of the
engagement of AhR-mediated signal transduction [17, 19].
Thus, these drugs, unlike other neoplastic agents, require
AhR-mediated signaling to cause DNA damage. This oﬀers a
new potential treatment strategy for breast cancers with
intact AhR signaling. Induction of CYP1A1 and AhR acti-
vation were considered as markers to predict sensitivity of
tumors to Bz and AF treatment in Phase I clinical trials.
The data presented in this paper indicate that the cyto-
plasmic AF-AhR complex can activate unliganded ER to en-
hance AhR target gene expression and as a result AF cyto-
toxicity [32]. Therefore, Phase II clinical trials of AF should
include hormone-resistant, metastatic breast cancers.
Also, these data indicated the usefulness of gene expres-
sion profiling in selecting patients for AF treatment. While
single-agent therapy might present an option for hormone
refractory luminal and basal A type patient populations,
breast cancer patients with basal B-like tumors will require
combination therapies, for example, with vorinostat [33, 34].
Pretreatment of TNBCs with vorinostat could sensitize these
tumors to AF, and this should be exploited in clinical trials.
AhR has a distinct distribution pattern in tumor cells. Cy-
toplasmic AhR expression elicits sensitivity to the AhR ligand
AF. If AhR is located in the nucleus, xenobiotic response is
impaired and AF cannot be activated [35]. Thus, immuno-
histological analysis of AhR should also be considered as a
tool in the upcoming Phase II trials in breast cancer to select
patients that are most likely to benefit from AF treatment.
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